We respect your privacy and use tracking simply to improve your experience - Read more Got it! Search Our governance framework Corporate governance HOME INVESTORS CORPORATE GOVERNANCE OUR GOVERNANCE FRAMEWORK Chairman's Introduction Tissue Regenix Group plc’s vision is to become a leader in regenerative medicine. This vision is underpinned by its core values to maintain a sustainable, ethical and responsible company. Sound corporate governance is a key part of this. As an AIM traded company, we recognise the need for ensuring that an effective governance framework is in place to give confidence to our investors, employees and other stakeholders in the business Compliance with QCA Corporate Governance Code We have agreed to report against the QCA Corporate Governance Code published by the Quoted Companies Alliance ("QCA Code") and this report sets out an overview of how we comply with the QCA Code at this point in time. We will provide updates as circumstances change. A full version of the QCA Code is available to download (free for members or for a fee for non-members) from the Quoted Companies Alliance website. Deliver Growth 1 "Establish a strategy and business model which promote long-term value for shareholders" Tissue Regenix Group has established a portfolio of regenerative medical products, based on two platform technologies, to address critical and increasing clinical needs, transforming patient care and providing favourable health economic outcomes. We aim to expand the adoption of our dCELL® and BioRinse® technologies and become a partner of choice for both clinicians and strategic partners. We aim to optimise the adoption of our products and drive additional revenues more rapidly through product line extensions, which have a quick route to market, and address specific clinical requirements where we see significant opportunities. Underpinning this, the business has adopted four key strategic growth drivers that it believes will accelerate market penetration and revenue growth, namely: accelerate US market penetration; exploit global market potential; broaden strategic partnerships; and strengthen the portfolio. More details of these strategic growth drivers can be found on pages 16 to 19 of the 2020 Annual Report. 2 "Seek to understand and meet shareholder needs and expectations" 3 "Take into account wider stakeholder and social responsibilities and their implications for long-terms success" 4 "Embed effective risk management, considering both opportunities and threats, throughout the organisation" Maintain a dynamic management framework 5 "Maintain the board as a well-functioning, balanced team led by the Chair" 6 "Ensure that between them the directors have the necessary up-to-date experience, skills and capabilities" 7 "Evaluate board performance based on clear and relevant objectives, seeking continuous improvement" 8 "Promote a corporate culture that is based on ethical values and behaviours" 9 "Maintain governance structures and processes that are fit for purpose and support good decision-making by the board" 10 "Communicate how the company is governed and is performing by maintaining a dialogue with shareholders and other relevant stakeholders" The Company maintains copies of all of its reports and accounts since 2010 on its website. 21 June 2021 You may also be interested in Audit committee Remuneration committee Board of Directors © 2021 Tissue Regenix PRODUCTS BioSurgery Orthopaedics Dental Cardiac USEFUL LINKS About us Accreditations and licenses Careers Contact us Investors FOLLOW US ON Twitter LinkedIn YouTube OUR SITES UK Visit https://www.tissueregenixus.com/investors/corporate-governance/our-governance-framework USA Accessibility Cookies Privacy policy Sitemap Terms of Use Designed and developed by Jones and Palmer